Home
ERNA
ERNA News

Latest Eterna Therapeutics Inc. (ERNA) News on September 3, 2025

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

GlobeNewswire

2 months ago

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

GlobeNewswire

2 months ago

Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement

MT Newswires

3 months ago

Eterna Therapeutics Files for Resale of 57 Million Shares

Ernexa Therapeutics announces 1-for-15 reverse stock split

TipRanks

3 months ago

Ernexa Therapeutics announces 1-for-15 reverse stock split

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

GlobeNewswire

3 months ago

Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

GlobeNewswire

3 months ago

Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

GlobeNewswire

4 months ago

Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations

Newsfile

4 months ago

Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

GlobeNewswire

4 months ago

Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

GlobeNewswire

4 months ago

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

MT Newswires

5 months ago

Eterna Therapeutics Insider Bought Shares Worth $394,174, According to a Recent SEC Filing

Ernexa Therapeutics Closes New Funding Round

GlobeNewswire

5 months ago

Ernexa Therapeutics Closes New Funding Round

GlobeNewswire

5 months ago

Eterna Therapeutics Changes Name to Ernexa Therapeutics to Reflect New Strategic Focus on Ovarian Cancer and Autoimmune Disease

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

GlobeNewswire

6 months ago

Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline

Eterna appoints Zeldis, Sather to scientific advisory board

TipRanks

7 months ago

Eterna appoints Zeldis, Sather to scientific advisory board

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

GlobeNewswire

7 months ago

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

MT Newswires

8 months ago

Top Midday Gainers

MT Newswires

8 months ago

Eterna Therapeutics Reports Positive Preclinical Results for Cancer Therapy ERNA-101; Shares Jump

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

GlobeNewswire

8 months ago

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

GlobeNewswire

8 months ago

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

GlobeNewswire

9 months ago

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

GlobeNewswire

9 months ago

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

GlobeNewswire

10 months ago

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

GlobeNewswire

10 months ago

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Eterna, Factor announce license, collaboration agreement

TipRanks

a year ago

Eterna, Factor announce license, collaboration agreement

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

GlobeNewswire

a year ago

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

GlobeNewswire

a year ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

GlobeNewswire

a year ago

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

GlobeNewswire

a year ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus

GlobeNewswire

a year ago

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

GlobeNewswire

2 years ago

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of January 31, 2024, for TYG, NTG, TTP, NDP and TPZ

ACCESSWIRE

2 years ago

Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of January 31, 2024, for TYG, NTG, TTP, NDP and TPZ

Lofty Unveils AI Powered Virtual Assistant at Inman Connect New York

GlobeNewswire

2 years ago

Lofty Unveils AI Powered Virtual Assistant at Inman Connect New York

Future FinTech Responds to Inquiry of CEO

PR Newswire

2 years ago

Future FinTech Responds to Inquiry of CEO

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

GlobeNewswire

2 years ago

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

GlobeNewswire

2 years ago

Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer

Volition Issues Business Review 2023

PR Newswire

2 years ago

Volition Issues Business Review 2023

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

GlobeNewswire

2 years ago

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Presidio Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire

2 years ago

Presidio Regains Compliance with Nasdaq Minimum Bid Price Requirement

Eterna Therapeutics Appoints Sanjeev Luther as President and CEO

Exec Edge

2 years ago

Eterna Therapeutics Appoints Sanjeev Luther as President and CEO

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

GlobeNewswire

2 years ago

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

11 Best Fundamentally Strong Penny Stocks To Invest In

Insider Monkey

2 years ago

11 Best Fundamentally Strong Penny Stocks To Invest In

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

GlobeNewswire

2 years ago

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Red Cat Holdings Selected by U.S. Army as Finalist for Short Range Reconnaissance Tranche 2 Drone Program

GlobeNewswire

2 years ago

Red Cat Holdings Selected by U.S. Army as Finalist for Short Range Reconnaissance Tranche 2 Drone Program

Imperial Petroleum Inc. Declares Dividend on Series A Preferred Shares

GlobeNewswire

2 years ago

Imperial Petroleum Inc. Declares Dividend on Series A Preferred Shares

Twin Vee PowerCats Co. and AquaSport Co. Subsidiary Announce the Launch of Three New Boat Models as Company Continues Its Growth Strategy with Innovative Product Development

ACCESSWIRE

2 years ago

Twin Vee PowerCats Co. and AquaSport Co. Subsidiary Announce the Launch of Three New Boat Models as Company Continues Its Growth Strategy with Innovative Product Development

SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts

GlobeNewswire

2 years ago

SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts

Idaho Strategic's Mineral Hill Sample Returns 34% Total Rare Earth Oxides (TREO)

ACCESSWIRE

2 years ago

Idaho Strategic's Mineral Hill Sample Returns 34% Total Rare Earth Oxides (TREO)

JOANN Inc. (NASDAQ:JOAN) Q3 2024 Earnings Call Transcript

Insider Monkey

2 years ago

JOANN Inc. (NASDAQ:JOAN) Q3 2024 Earnings Call Transcript

Spectral AI to Participate in Benchmark’s 12th Annual Discovery One-on-One Conference

GlobeNewswire

2 years ago

Spectral AI to Participate in Benchmark’s 12th Annual Discovery One-on-One Conference

Bright Green Announces Third Quarter 2023 Financial Update and Milestone Progress

GlobeNewswire

2 years ago

Bright Green Announces Third Quarter 2023 Financial Update and Milestone Progress

PR Newswire

2 years ago

ATRenew Inc. Reports Unaudited Third Quarter 2023 Financial Results

Farmer Bros Interim Independent Chairman of the Board Acquires 94% More Stock

Simply Wall St.

2 years ago

Farmer Bros Interim Independent Chairman of the Board Acquires 94% More Stock

U.S. Gold Corp. to Participate at 2023 Mines and Money @ Resourcing Tomorrow Conference in London

PR Newswire

2 years ago

U.S. Gold Corp. to Participate at 2023 Mines and Money @ Resourcing Tomorrow Conference in London

FreightCar America's (NASDAQ:RAIL) Returns On Capital Are Heading Higher

Simply Wall St.

2 years ago

FreightCar America's (NASDAQ:RAIL) Returns On Capital Are Heading Higher

Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

GlobeNewswire

2 years ago

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Espey Mfg. & Electronics Corp. reports first quarter results

GlobeNewswire

2 years ago

Espey Mfg. & Electronics Corp. reports first quarter results

Carbon Revolution Issues Investor Presentation Ahead of Appearance at 14th Annual Craig-Hallum Alpha Select Conference

GlobeNewswire

2 years ago

Carbon Revolution Issues Investor Presentation Ahead of Appearance at 14th Annual Craig-Hallum Alpha Select Conference

Hyperfine, Inc. (NASDAQ:HYPR) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Hyperfine, Inc. (NASDAQ:HYPR) Q3 2023 Earnings Call Transcript

Sadot Group Inc. Announces Third Quarter 2023 Conference Call

ACCESSWIRE

2 years ago

Sadot Group Inc. Announces Third Quarter 2023 Conference Call

Bragg Gaming Group Third Quarter Revenue Rises 8.0% Year Over Year to €22.6 Million (USD $24.0 Million)

Business Wire

2 years ago

Bragg Gaming Group Third Quarter Revenue Rises 8.0% Year Over Year to €22.6 Million (USD $24.0 Million)

PR Newswire

2 years ago

ATRenew to Report Third Quarter 2023 Financial Results on November 22, 2023

PR Newswire

2 years ago

ATRenew Recognized by the Reuters Responsible Business Awards 2023

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

PR Newswire

2 years ago

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

GlobeNewswire

2 years ago

HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023

Nortech Welcomes Two New Board Members

Business Wire

2 years ago

Nortech Welcomes Two New Board Members

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Newsfile

2 years ago

Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

Share on Social Networks: